| A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. | |
| | |
MedLine Citation:
|
PMID: 22294625 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
PurposeTo compare the effectiveness of anti-tumour necrosis factor (TNF) agents in biologically naive and 'switched' rheumatoid arthritis (RA) patients.METHODS: RA patients enrolled in the CORRONA registry newly prescribed adalimumab (n=874), etanercept (n=640), or infliximab (n=728) were stratified based on previous anti-TNF use. Clinical effectiveness at 6, 12 and 24 months was examined using the modified American College of Rheumatology response criteria (mACR20/50/70) and achievement of remission (28-joint disease activity score (DAS28) and clinical disease activity index (CDAI)) in unadjusted and adjusted analyses. The persistence of anti-TNF treatment was examined using Cox proportional hazard models.RESULTS: Among 2242 patients (1475 biologically naive, 767 switchers), mACR20, 50 and 70 responses were similar (p>0.05) for adalimumab, etanercept and infliximab at all time points, as were rates of CDAI and DAS28 remission (p>0.05). Response and remission outcomes were consistently inferior for switched versus biologically naive patients. The adjusted OR for achieving an mACR20 response was 0.54 (95% CI 0.38 to 0.76) in first-time switchers and 0.42 (95% CI 0.23 to 0.78) in second-time switchers versus biologically naive patients at 6 months. The adjusted OR for achieving DAS28 remission were 0.29 (95% CI 0.15 to 0.58) for first-time switchers and 0.26 (95% CI 0.08 to 0.84) for second-time switchers. Persistence was higher in biologically naive patients, for whom persistence was highest with infliximab.CONCLUSIONS: No differences in rates of drug response or remission were observed among the three anti-TNF. Infliximab was associated with greater persistence in biologically naive patients. Response, remission and persistence outcomes were diminished for patients who switched anti-TNF. |
| | |
Authors:
|
Jeffrey D Greenberg; George Reed; Dennis Decktor; Leslie Harrold; Daniel Furst; Allan Gibofsky; Ralph Dehoratius; Mitsumasa Kishimoto; Joel M Kremer; |
Related Documents
:
|
20361215 - Stereotactic radiofrequency amygdalohippocampectomy in the treatment of mesial temporal... 6941925 - Genetic markers in epilepsy: a survey. 16401735 - Neuropathologic substrate of mild cognitive impairment. 3491655 - Effects of thalamic stroke on energy metabolism of the cerebral cortex. a positron tomo... 18308805 - Use of aripiprazole in treatment resistant schizophrenia. 8039725 - Alzheimer's disease: a comprehensive approach to patient management. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-1-30 |
Journal Detail:
|
Title: Annals of the rheumatic diseases Volume: - ISSN: 1468-2060 ISO Abbreviation: - Publication Date: 2012 Jan |
Date Detail:
|
Created Date: 2012-2-1 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0372355 Medline TA: Ann Rheum Dis Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
1New York University Hopsital for Joint Diseases, New York, New York, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Cytokine levels in human synovial fluid during the different stages of acute gout: role of transform...
Next Document: Anti-TIF1? antibodies (anti-p155) in adult patients with dermatomyositis: comparison of different di...